<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140624018210N10</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-12-13</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Formulation and manufacturing of corticosteroid free ointment for treatment of eczema</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the efficacy of corticosteroid free ointment in the treatment of patient with eczema</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-12-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>75</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/52718</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization is a commonly used technique in clinical trial design to reduce bias and achieve balance in the allocation of participants to treatment arms. This method increases the probability that each arm will contain an  
equal number of individuals by sequencing participant assignments by block.The randomization unit is individual and randomization's tool is a statistical software.randomization is a simple method using statistical software SPSS version 22.Both drugs are packaged in the same container of 100 grams. The randomization list is prepared by a statistical consultant and a number is given to each medicine container. The participant and the main researcher and the doctor who is responsible for following up the patient and evaluating the outcome of the drug use are not aware of the nature of the drug used, Blinding description: In this study, the outcome assessor and participants have been blinded. The outcome assessor is people who are responsible for gathering data and outcome variables and does not know which participant received which drug.</study_design>
      <phase>3</phase>
      <hc_freetext>eczema.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: A group treated with formulated ointment containing active ingredients .                                                                                                                     Formulation:1)First, dissolve 8 grams of carbomer in one and a half liters of water and then bring the dissolved carbomer to a temperature of 70 degrees Celsius.2)In the next step, sterile acetyl alcohol + acetyl alcohol + liquid paraffin + GMS 32 g + stearate 20, + dimethicone + Vaseline is added and placed on the heater to dissolve completely.3)The active ingredients are weighed on the scales and added to the container, respectively. The active ingredients: omega 6 (linoleic acid) + zinc oxide + biotin + vitamin B6 + vitamin B12 + menthol were added one gram. It should be noted that the active ingredients are micronized4)Then items 1 and 2 were mixed together and homogenized with a homogenizer and finally triethanolamine was added.5)Methyl isothiosolonium preservative was added for 400C.       all patients have signatured informed consent documents and were given a complete explanation about the sudy procedures        .after the first visit and examination, patients would start the treatment period and after a month of treatment would be re-examined for treatment efficacy and followup checkups.          treatment dosage is variable from 2 to 10 gr and should be administred on the lesion two times per day.        oinment administration procedure is dependent on lesion size and each patient should use the oinment based on their lesion size in a manner that the surface of lesion shoud be fully covered with the oinment.       The place of cream formulation has been done in Oud Kala factory (Alborz province, Baharestan town, Golestan 10th, Oud Kala factory (health-pharmaceutical products factory)). Intervention 2: Intervention group: A group that uses standard ointments such as eucerin. Intervention 3: Control group: A group treated with ointments without active ingredients.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is No - There is not a plan to make this available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Nuredin Bakhtiari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran - Shahid Babaei Highway (west to east) - Hakimiyeh exit - Shahid Sadoughi St. - Shahid Abbaspour Boulevard - Islamic Azad University North Tehran Branch</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1493889878</zip>
        <telephone>+98 21 4476 4532</telephone>
        <email>nuredin1480@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Elham Behrangi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dermatology Department,Rasool-Akram-Hospital,Satarkhan Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6650 2040</telephone>
        <email>behrangi.e@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Only patients with active eczema lesions are included in this study.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with very large (severe) lesions
Patients with a history of skin diseases other than eczema</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L20.89</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other atopic dermatitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: A group treated with formulated ointment containing active ingredients .                                                                                                                     Formulation:1)First, dissolve 8 grams of carbomer in one and a half liters of water and then bring the dissolved carbomer to a temperature of 70 degrees Celsius.2)In the next step, sterile acetyl alcohol + acetyl alcohol + liquid paraffin + GMS 32 g + stearate 20, + dimethicone + Vaseline is added and placed on the heater to dissolve completely.3)The active ingredients are weighed on the scales and added to the container, respectively. The active ingredients: omega 6 (linoleic acid) + zinc oxide + biotin + vitamin B6 + vitamin B12 + menthol were added one gram. It should be noted that the active ingredients are micronized4)Then items 1 and 2 were mixed together and homogenized with a homogenizer and finally triethanolamine was added.5)Methyl isothiosolonium preservative was added for 400C.       all patients have signatured informed consent documents and were given a complete explanation about the sudy procedures        .after the first visit and examination, patients would start the treatment period and after a month of treatment would be re-examined for treatment efficacy and followup checkups.          treatment dosage is variable from 2 to 10 gr and should be administred on the lesion two times per day.        oinment administration procedure is dependent on lesion size and each patient should use the oinment based on their lesion size in a manner that the surface of lesion shoud be fully covered with the oinment.       The place of cream formulation has been done in Oud Kala factory (Alborz province, Baharestan town, Golestan 10th, Oud Kala factory (health-pharmaceutical products factory))</i_keyword>
      <i_keyword>Intervention group: A group that uses standard ointments such as eucerin</i_keyword>
      <i_keyword>Control group: A group treated with ointments without active ingredients</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>1) itching 2) redness 3) burning 4) inflammation 5) wound healing. Timepoint: End of the treatment period. Method of measurement: Clinical examination.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-11-30</approval_date>
        <contact_name>Ethic committee of Iran University Of Medical sience</contact_name>
        <contact_address>Iran university -Hemat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
